What are the indications for intravenous immunoglobulin (IVIG) in a patient with suspected Guillain‑Barré syndrome (GBS)?

Indications for IVIG in Suspected GBS

IVIG should be initiated in patients with suspected GBS who are unable to walk independently (GBS disability score ≥3) and present within 2 weeks of symptom onset, with treatment potentially beneficial up to 4 weeks after onset. 1

Primary Treatment Criteria

The decision to start IVIG hinges on two key factors:

1. Severity of Weakness

• Non-ambulatory patients (cannot walk 5 meters without assistance) are the clearest indication for treatment 1
• Ambulatory patients may be considered for treatment if examined within 2 weeks of onset and showing rapid progression 2
• The standard dosing is 0.4 g/kg daily for 5 consecutive days 1

2. Timing from Symptom Onset

• Optimal window: Within 2 weeks - This is when IVIG demonstrates maximal benefit 1, 3
• Extended window: Up to 4 weeks - Treatment may still be considered, though efficacy diminishes significantly after 2 weeks 4, 3
• Beyond 4 weeks: Alternative diagnoses (particularly A-CIDP) should be strongly considered before treating 5

Clinical Features Supporting Treatment Decision

Look for these specific findings to confirm GBS diagnosis before initiating IVIG:

• Bilateral progressive weakness starting in legs, progressing to arms/cranial muscles
• Areflexia or hyporeflexia (present in almost all patients at nadir) 1
• Rapid progression reaching maximum disability within 2 weeks (not <24 hours or >4 weeks) 1
• Absence of CNS involvement or other obvious causes 1

Special Populations

Children

• Same criteria apply as adults 1
• IVIG is preferred over plasma exchange due to better tolerability 1, 6
• Use standard 5-day regimen (0.4 g/kg/day) rather than 2-day regimen to reduce treatment-related fluctuations 1

Pregnant Women

• IVIG is not contraindicated and is preferred over plasma exchange 1

GBS Variants

• Miller Fisher Syndrome (pure): Generally do NOT treat - most recover completely without intervention within 6 months 1
• Other variants (pure motor, pharyngeal-cervical-brachial, paraparetic): Treat if meeting severity criteria 1
• Bickerstaff brainstem encephalitis: Treat due to severe disease course 1

Critical Pitfalls to Avoid

1. Do NOT combine IVIG with plasma exchange - No additional benefit and potentially harmful 1, 2, 7

2. Do NOT repeat IVIG in non-responders - Recent evidence suggests no benefit and possible harm 8, 5. If no improvement after first course, consider plasma exchange as rescue therapy instead

3. Do NOT add corticosteroids - Eight RCTs show no benefit; oral corticosteroids may worsen outcomes 1, 2

4. Distinguish from A-CIDP - If progression continues beyond 4 weeks or patient requires repeat dosing, reconsider diagnosis as acute-onset CIDP rather than GBS 5

Contraindications

Absolute contraindications 9:

• History of anaphylaxis to human immunoglobulin
• IgA deficiency with anti-IgA antibodies and prior hypersensitivity

Relative cautions requiring dose/rate adjustment 9:

• Pre-existing renal insufficiency
• Age >65 years
• Volume depletion
• Diabetes mellitus
• Thrombotic risk factors (use minimum infusion rate, ensure hydration)

Monitoring Requirements

Before initiating IVIG, ensure:

• Patient is adequately hydrated 9
• Baseline renal function (BUN, creatinine) documented 9
• Respiratory function assessed (vital capacity, single breath count) 1

The evidence strongly supports IVIG as first-line therapy for moderate-to-severe GBS when initiated early, with plasma exchange reserved as an alternative (not additive) treatment option.